M. J. Van-den-bent, B. Baumert, S. C. Erridge, M. A. Vogelbaum, A. K. Nowak et al., Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study, Lancet Lond Engl, pp.31442-31445, 2017.

D. N. Louis, A. Perry, G. Reifenberger, A. Von-deimling, D. Figarella-branger et al., The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol (Berl), vol.131, issue.803, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

J. G. Cairncross, K. Ueki, M. C. Zlatescu, D. K. Lisle, D. M. Finkelstein et al., Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas, J Natl Cancer Inst, vol.90, pp.1473-1482, 1998.

M. J. Van-den-bent, A. F. Carpentier, A. A. Brandes, M. Sanson, M. Taphoorn et al., Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial, J Clin Oncol, vol.24, pp.2715-2737, 2006.

G. Cairncross, B. Berkey, E. Shaw, R. Jenkins, and B. Scheithauer, Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup Radiation Therapy Oncology Group Trial 9402, Intergroup Radiation Therapy Oncology Group Trial 9402, vol.24, pp.2707-2721, 2006.

M. J. Van-den-bent, A. A. Brandes, M. Taphoorn, J. M. Kros, M. Kouwenhoven et al., Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951, J Clin Oncol, vol.31, 2013.

G. Cairncross, M. Wang, E. Shaw, R. Jenkins, D. Brachman et al., Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402, J Clin Oncol, vol.31, 2013.

J. C. Buckner, E. G. Shaw, S. L. Pugh, A. Chakravarti, M. R. Gilbert et al., Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma, N Engl J Med, vol.374, pp.1344-55, 2016.

M. Weller, M. Van-den-bent, J. C. Tonn, R. Stupp, M. Preusser et al., European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas, Lancet Oncol, vol.18, pp.30194-30202, 2017.

W. Wick, C. Hartmann, C. Engel, M. Stoffels, J. Felsberg et al., NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide, J Clin Oncol, vol.27, pp.5874-80, 2009.

W. Wick, P. Roth, C. Hartmann, P. Hau, M. Nakamura et al., Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide, Neuro-Oncol, vol.18, pp.1529-1566, 2016.

B. G. Baumert, M. E. Hegi, M. J. Van-den-bent, V. Deimling, A. Gorlia et al., Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study, Lancet Oncol, vol.17, issue.16, pp.30313-30321, 2016.

E. Habets, M. Taphoorn, S. Nederend, M. Klein, D. Delgadillo et al., Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors, J Neurooncol, vol.116, pp.161-169, 2014.

K. Gehring, M. M. Sitskoorn, C. M. Gundy, S. Sikkes, M. Klein et al., Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial, J Clin Oncol, vol.27, pp.3712-3734, 2009.

J. G. Cairncross, M. Wang, R. B. Jenkins, E. G. Shaw, C. Giannini et al., Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH, J Clin Oncol, vol.32, pp.783-90, 2014.

M. J. Van-den-bent, L. A. Gravendeel, T. Gorlia, J. M. Kros, L. Lapre et al., A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951, Clin Cancer Res, vol.17, 2011.

B. Wiestler, D. Capper, M. Sill, D. Jones, V. Hovestadt et al., Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma, Acta Neuropathol (Berl), vol.128, pp.561-71, 2014.

M. Weller, R. G. Weber, E. Willscher, V. Riehmer, B. Hentschel et al., Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome-and transcriptome-wide profiling improves stratification of prognostically distinct patient groups, Acta Neuropathol (Berl), vol.129, pp.679-93, 2015.

D. E. Reuss, A. Kratz, F. Sahm, D. Capper, D. Schrimpf et al., Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities, Acta Neuropathol (Berl), vol.130, 2015.

E. G. Shaw, B. Berkey, S. W. Coons, D. Bullard, D. Brachman et al., Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial, J Neurosurg, vol.109, pp.835-876, 2008.